Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSBR 
Champions Oncology Inc (CSBR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CSBR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.31% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.44M USD | Price to earnings Ratio 20.75 | 1Y Target Price 12 |
Price to earnings Ratio 20.75 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 3.75 - 11.99 | Updated Date 09/15/2025 |
52 Weeks Range 3.75 - 11.99 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-09-09 | When Before Market | Estimate 0.06 | Actual 0.02 |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) -13.87% |
Management Effectiveness
Return on Assets (TTM) 10.36% | Return on Equity (TTM) 50.31% |
Valuation
Trailing PE 20.75 | Forward PE 22.88 | Enterprise Value 90494915 | Price to Sales(TTM) 2.01 |
Enterprise Value 90494915 | Price to Sales(TTM) 2.01 | ||
Enterprise Value to Revenue 1.59 | Enterprise Value to EBITDA 13.95 | Shares Outstanding 13788400 | Shares Floating 5196197 |
Shares Outstanding 13788400 | Shares Floating 5196197 | ||
Percent Insiders 26.18 | Percent Institutions 48.17 |
Upturn AI SWOT
Champions Oncology Inc
Company Overview
History and Background
Champions Oncology Inc. was founded in 2007. It specializes in providing preclinical oncology solutions, primarily Patient-Derived Xenograft (PDX) models and related services, to biopharmaceutical companies developing new cancer therapies. Initially focused on in vivo models, it has expanded into ex vivo and in silico platforms.
Core Business Areas
- In Vivo Services: Champions Oncology's core business involves creating and utilizing Patient-Derived Xenograft (PDX) models. These models involve implanting human tumor tissue into immunodeficient mice, allowing researchers to study tumor growth, drug response, and biomarker identification in a living system that closely resembles the human cancer environment.
- Ex Vivo Services: These services include cutting-edge platforms, such as cell-based assays, bioprinting, and 3D tumor models, providing faster and more scalable screening tools. These technologies allow for high-throughput drug screening and personalized medicine approaches.
- In Silico Services: Champions Oncology offers computational biology and bioinformatics services, which involve analyzing large datasets derived from PDX models and other sources. This allows for the identification of predictive biomarkers, drug target discovery, and the development of computational models to simulate drug response.
Leadership and Structure
Champions Oncology Inc. is led by a management team with expertise in oncology, drug development, and business operations. The organizational structure is designed to support its core business segments, with dedicated teams for in vivo, ex vivo, and in silico services. Executive leadership includes a CEO, CFO, and other key positions overseeing research, operations, and commercial activities.
Top Products and Market Share
Key Offerings
- Patient-Derived Xenograft (PDX) Models: PDX models form the cornerstone of Champions Oncology's offerings. These models are used by biopharmaceutical companies to preclinical test drug efficacy and predict patient response. Champions Oncology holds a significant market share, with strong penetration in the oncology preclinical testing market. Competitors include The Jackson Laboratory (JAX) and Charles River Laboratories. Revenue from PDX models constitutes the majority of the company's revenue.
- Ex Vivo and In Silico Platforms: These offerings include cell-based assays, bioprinting, 3D tumor models and computational biology. These platforms provide high-throughput drug screening, biomarker identification, and computational modeling to accelerate cancer drug development. Competitors include Crown Bioscience and WuXi AppTec.
Market Dynamics
Industry Overview
The oncology preclinical testing market is driven by the increasing need for personalized medicine, the rising incidence of cancer, and the growing investment in cancer drug development. The market is characterized by technological advancements, increasing regulatory scrutiny, and a focus on translational research.
Positioning
Champions Oncology Inc. holds a strong position in the preclinical oncology testing market, particularly with its expertise in PDX models and comprehensive service offerings. Its competitive advantages include its extensive library of PDX models, its integrated service platform, and its scientific expertise.
Total Addressable Market (TAM)
The global preclinical oncology market is estimated to be worth billions of USD, and Champions Oncology is positioned to capture a significant share through its offerings.
Upturn SWOT Analysis
Strengths
- Extensive PDX model library
- Integrated service platform
- Strong scientific expertise
- Established relationships with biopharmaceutical companies
Weaknesses
- High operating costs
- Limited geographic presence
- Dependence on PDX models
- Reliance on research grants and contracts
Opportunities
- Expanding into new geographic markets
- Developing new ex vivo and in silico platforms
- Partnering with academic institutions
- Leveraging artificial intelligence and machine learning
Threats
- Increased competition
- Technological disruptions
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- JAX
- CRIS
- WUXI
Competitive Landscape
Champions Oncology Inc. faces competition from larger players with broader service offerings. However, its focus on PDX models and its integrated service platform provide a competitive advantage. Its strong relationships with biopharmaceutical companies and scientific expertise differentiate it from its competitors.
Major Acquisitions
Personalized Biomarker Solutions
- Year: 2018
- Acquisition Price (USD millions): 12.6
- Strategic Rationale: The acquisition of Personalized Biomarker Solutions (PBS) provided Champions Oncology with proprietary platforms for ex vivo modeling, which enhanced their preclinical and translational service offerings.
Growth Trajectory and Initiatives
Historical Growth: Data unavailable without real-time access to financial databases.
Future Projections: Data unavailable without real-time access to financial databases.
Recent Initiatives: Champions Oncology is focused on expanding its service offerings beyond PDX models, including cell-based assays, bioprinting, and computational biology. They are also actively pursuing partnerships and collaborations to expand their geographic reach and technological capabilities.
Summary
Champions Oncology holds a strong position in preclinical oncology solutions, primarily through its PDX models. The company's integrated platform and scientific expertise differentiate it from competitors. However, the company needs to watch out for emerging new technologies from large corporations and ensure they are competitive in that segment as well.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Champions Oncology Inc
Exchange NASDAQ | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 2003-01-10 | CEO & Director Mr. Robert Brainin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | |
Full time employees 213 | |||
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.